AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
{{expandStatus?'Exit ':''}}Advanced Search
The Annual Report on Cardiovascular Health and Diseases in China (2022) intricate landscape of cardiovascular health in China. This is the fourth section of the report with a specific focus on epidemiology and current management of cardiovascular disease (CVD) in China. This section of the report highlights the epidemiological trends of CVD in China. It reveal a concerning rise in prevalence, with approximately 330 million affected individuals, including significant numbers with stroke, coronary artery disease (CAD), heart failure, and other conditions. CVD stands as the primary cause of mortality among both urban and rural populations, accounting for nearly half of all deaths in 2020. Mortality rates are notably higher in rural areas compared to urban centers since 2009. While age-standardized mortality rates have decreased, the absolute number of CVD deaths has increased, primarily due to population aging. Ischemic heart disease, hemorrhagic and ischemic strokes are the leading causes of CVD-related deaths. Notably, the burden of atherosclerotic cardiovascular disease has risen substantially, with atherosclerotic cardiovascular disease-related deaths increasing from 1990 to 2016. The incidence of ischemic stroke and ischemic heart disease has shown similar increasing trends over the past three decades. CAD mortality, particularly acute myocardial infarction, has been on the rise, with higher mortality rates observed in rural areas since 2016. The prevalence of CAD has increased significantly, with over 11 million patients identified in 2013. Studies assessing hospital performance in managing acute coronary syndrome reveal gaps in adherence to guideline-recommended strategies, with disparities in care quality across hospitals. However, initiatives like the China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study and the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS) project aim to improve patient outcomes through enhanced care protocols. Moreover, advancements in medical technology, such as quantitative flow ratio-guided lesion selection during percutaneous coronary intervention, show promise in improving clinical outcomes for patients undergoing intervention.
Wang W, Liu YN, Liu JM, et al. Mortality and years of life lost of cardiovascular diseases in China, 2005–2020: empirical evidence from national mortality surveillance system. Int J Cardiol 2021; 340: 105−112.
Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol 2019; 16: 203−212.
Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583−612.
Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health 2013; 1: e259−e281.
Zhang GS, Yu CH, Zhou MG, et al. Burden of ischaemic heart disease and attributable risk factors in China from 1990 to 2015: findings from the global burden of disease 2015 study. BMC Cardiovasc Disord 2018; 18: 18.
Wang WZ, Jiang B, Sun HX, et al. Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480, 687 adults. Circulation 2017; 135: 759−771.
Moran A, Gu DF, Zhao D, et al. Future cardiovascular disease in China: Markov model and risk factor scenario projections from the Coronary Heart Disease Policy Model-China. Circ Cardiovasc Qual Outcomes 2010; 3: 243−252.
Moran A, Zhao D, Gu DF, et al. The future impact of population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model-China. BMC Public Health 2008; 8: 394.
Li J, Li X, Wang Q, et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet 2015; 385: 441−451.
Zhang Q, Zhao D, Xie WX, et al. Recent trends in hospitalization for acute myocardial infarction in Beijing: increasing overall burden and a transition from ST-segment elevation to non-ST-segment elevation myocardial infarction in a population-based study. Medicine (Baltimore) 2016; 95: e2677.
Zhao QH, Yang YJ, Chen ZJ, et al. Changes in characteristics, risk factors, and in-hospital mortality among patients with acute myocardial infarction in the capital of China over 40 years. Int J Cardiol 2018; 265: 30−34.
Xu HY, Yang YJ, Wang CS, et al. Association of hospital-level differences in care with outcomes among patients with acute ST-segment elevation myocardial infarction in China. JAMA Netw Open 2020; 3: e2021677.
Zhao YY, Yang JG, Xu HB, et al. Correlation analysis of medical quality and in-hospital mortality of acute ST-segment elevation myocardial infarction in China. Chin Circ J 2019; 34: 437−443.
Song CX, Fu R, Yang JG, et al. The association between body mass index and in-hospital outcome among patients with acute myocardial infarction: insights from China Acute Myocardial Infarction (CAMI) registry. Nutr Metab Cardiovasc Dis 2019; 29: 808−814.
He L, Lu F, Du X, et al. Impact of COVID-19 pandemic on hospital admissions of acute coronary syndrome: a Beijing inpatient database study. Lancet Reg Health West Pac 2022; 19: 100335.
Luo S, Qiu XM, Zeng XJ, et al. Coronary artery calcification and risk of mortality and adverse outcomes in patients with COVID-19: a Chinese multicenter retrospective cohort study. Chin J Acad Radiol 2022; 5: 20−28.
Xu B, Tu SX, Song L, et al. Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. Lancet 2021; 398: 2149−2159.
Zhang R, Dou KF, Guan CD, et al. Outcomes of quantitative flow ratio-based percutaneous coronary intervention in an all-comers study. EuroIntervention 2022; 17: 1240−1251.
Liu X, Mo XK, Zhang HY, et al. A 2-year investigation of the impact of the computed tomography-derived fractional flow reserve calculated using a deep learning algorithm on routine decision-making for coronary artery disease management. Eur Radiol 2021; 31: 7039−7046.
Yu YR, Yu LH, Dai X, et al. CT fractional flow reserve for the diagnosis of myocardial bridging-related ischemia: a study using dynamic CT myocardial perfusion imaging as a reference standard. Korean J Radiol 2021; 22: 1964−1973.
Wang YB, Chen HW, Sun T, et al. Risk predicting for acute coronary syndrome based on machine learning model with kinetic plaque features from serial coronary computed tomography angiography. Eur Heart J Cardiovasc Imaging 2022; 23: 800−810.
Wang Y, Zhao XX, Zhou P, et al. Residual SYNTAX score in relation to coronary culprit plaque characteristics and cardiovascular risk in ST-segment elevation myocardial infarction: an intravascular optical coherence tomography study. J Cardiovasc Transl Res 2022; 15: 75−83.
Jiang J, Li CG, Hu YM, et al. A novel CFD-based computed index of microcirculatory resistance (IMR) derived from coronary angiography to assess coronary microcirculation. Comput Methods Programs Biomed 2022; 221: 106897.
Lin JR, Wu WC, Gao LJ, et al. Global myocardial work combined with treadmill exercise stress to detect significant coronary artery disease. J Am Soc Echocardiogr 2022; 35: 247−257.
Mu D, Bai JJ, Chen WP, et al. Calcium scoring at coronary CT angiography using deep learning. Radiology 2022; 302: 309−316.
Liu CY, Tang CX, Zhang XL, et al. Deep learning powered coronary CT angiography for detecting obstructive coronary artery disease: the effect of reader experience, calcification and image quality. Eur J Radiol 2021; 142: 109835.
Ma HP, Lin S, Li X, et al. Optimal heart team protocol to improve revascularization decisions in patients with complex coronary artery disease: a sequential mixed method study. Eur Heart J Qual Care Clin Outcomes 2022; 8: 739−749.
Hao YC, Zhao D, Liu J, et al. Performance of management strategies with class I recommendations among patients hospitalized with ST-segment elevation myocardial infarction in China. JAMA Cardiol 2022; 7: 484−491.
Ni Z, Wu B, Yang Q, et al. An mHealth intervention to improve medication adherence and health outcomes among patients with coronary heart disease: randomized controlled trial. J Med Internet Res 2022; 24: e27202.
Sun PF, Li JP, Fang WY, et al. Effectiveness of chest pain centre accreditation on the management of acute coronary syndrome: a retrospective study using a national database. BMJ Qual Saf 2021; 30: 867−875.
Zhang ZF, Si DY, Zhang Q, et al. Prophylactic rivaroxaban therapy for left ventricular thrombus after anterior ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2022; 15: 861−872.
Hu X, Wang W, Ye J, et al. Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon. Biomed Pharmacother 2021; 143: 112196.
Zheng B, Li JP, Jiang J, et al. Safety and efficacy of a platelet glycoprotein Ib inhibitor for patients with non-ST-segment elevation myocardial infarction: a phase Ib/IIa study. Pharmacotherapy 2021; 41: 828−836.
Zhao X, Ma SC, Kang Y, et al. Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J Cardiovasc Pharmacother 2022; 8: 806−814.
Zheng YY, Wu TT, Yang Y, et al. Diabetes and outcomes following personalized antiplatelet therapy in coronary artery disease patients who have undergone PCI. J Clin Endocrinol Metab 2022; 107: e214−e223.
Wu F, Liu X, Ran H, et al. Safety profile of bivalirudin in Chinese female patients undergoing percutaneous coronary intervention: a multi-center study. BMC Cardiovasc Disord 2022; 22: 58.
Yan Y, Gong W, Ma CS, et al. Postprocedure anticoagulation in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv 2022; 15: 251−263.
Xu S, Li Z, Yang T, et al. Association between early oral β-blocker therapy and risk for in-hospital major bleeding after percutaneous coronary intervention for acute coronary syndrome: findings from CCC-ACS project. Eur Heart J Qual Care Clin Outcomes 2022; 17: qcac036.
Zhou MG, Zhang J, Liu J, et al. Proton pump inhibitors and in-hospital gastrointestinal bleeding in patients with acute coronary syndrome receiving dual antiplatelet therapy. Mayo Clin Proc 2022; 97: 682−692.
Xu K, Fu GS, Tong Q, et al. Biolimus-coated balloon in small-vessel coronary artery disease: the BIO-RISE CHINA study. JACC Cardiovasc Interv 2022; 15: 1219−1226.
He Y, Wang RT, Liu JZ, et al. A randomized comparison of the healing response between the Firehawk stent and the Xience stent inpatients with ST-segment elevation myocardial infarction at 6 months of follow-up (TARGET STEMI OCT China Trial): an optical coherence tomography study. Front Cardiovasc Med 2022; 9: 895167.
Ferdous MM, Jie Z, Gao L, et al. A first-in-human study of the Bioheart sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease: two-year clinical and imaging outcomes. Adv Ther 2022; 39: 3749−3765.
Hu FW, Chang S, Li Q, et al. Long-term clinical outcomes after percutaneous coronary intervention with drug-coated balloon-only strategy in lesions of large coronary arteries. Front Cardiovasc Med 2022; 9: 882303.
Zhong X, Gao W, Hu T, et al. Impact of subintimal pl aque modification on reattempted chronic total occlus ions percutaneous coronary intervention. JACC Cardio vasc Interv 2022; 15: 1427−1437.
Hu MJ, Peng Y, Gao XJ, et al. Coronary intervention in ST-segment elevation myocardial infarction patients with symptom onset > 12 hours: data from China Acute Myocardial Infarction registry. Angiology 2023; 74: 171−180.
Gao K, Li BL, Zhang M, et al. Long-term outcomes of percutaneous coronary intervention for patients within-stent chronic total occlusion versus de novo chronic total occlusion. Angiology 2021; 72: 740−748.
Tian MC, Wang XQ, Sun HS, et al. No-touch versus conventional vein harvesting techniques at 12 months after coronary artery bypass grafting surgery: multicenter ra ndomized, controlled trial. Circulation 2021; 144: 1120−1129.
Zhou ZM, Liang MY, Zhuang XD, et al. Long-term outcomes after on-pump vs off-pump coronary artery bypass grafting for ischemic cardiomyopathy. Ann Thorac Surg 2023; 115: 1421−1428.
Zhu ZB, Zhu JZ, Yu JW, et al. Percutaneous ventricular restoration prevents left ventricular remodeling post myocardial infarction: one-year evaluation of the Heartech first-in-man study. J Card Fail 2022; 28: 604−613.
Lin S, Guan CD, Wu F, et al. Coronary artery bypass grafting and percutaneous coronary intervention in patients with chronic total occlusion and multivessel disease. Circ Cardiovasc Interv 2022; 15: e011312.
Wang K, Wang L, Cong HL, et al. A comparison of drug-eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure. ESC Heart Fail 2022; 9: 1749−1755.
Zhao XY, Xu LJ, Jiang L, et al. Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China. Cardiovasc Diabetol 2021; 20: 16.
Fan Q, Liu J, Xu Y, et al. Real-world outcomes of revascularization strategies in patients with left ventricular dysfunction and three-vessel coronary disease stratified by mitral regurgitation. Front Cardiovasc Med 2021; 8: 675722.
Wang ES, Yuan X, Wang Y, et al. Blood conservation outcomes and safety of tranexamic acid in coronary artery bypass graft surgery. Int J Cardiol 2022; 348: 50−56.
Li X, Gu DC, Wang XQ, et al. Trends of coronary artery bypass grafting performance in a cohort of hospitals in China between 2013 and 2018. Circ Cardiovasc Qual Outco mes 2021; 14: e007025.
Zhang DW, Gu DC, Rao CF, et al. Outcome differences between surgeons performing first and subsequent coronary artery bypass grafting procedures in a day: a retrospective comparative cohort study. BMJ Qual Saf 2023; 32: 192−201.
Yang SC, Han YT, Yu CQ, et al. Development of a model to predict 10-year risk of ischemic and hemorrhagic stroke and ischemic heart disease using the China Kadoorie Biobank. Neurology 2022; 98: e2307−e2317.
Lu XF, Liu ZY, Cui QM, et al. A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study. Eur Heart J 2022; 43: 1702−1711.
Zhao XY, Li JW, Liu FC, et al. The PRECISE-DAPT score and five-year outcomes after percutaneous coronary intervention: a large-scale, real-world study from China. Eur Heart J Qual Care Clin Outcomes 2022; 8: 812−820.
Xu W, Yang YM, Zhu J, et al. Predictive value of the stress hyperglycemia ratio in patients with acute ST-segment elevation myocardial infarction: insights from a multi-center observational study. Cardiovasc Diabetol 2022; 21: 48.
Song L, Wang Y, Guan CD, et al. Impact of periprocedural myocardial injury and infarction definitions on long- term mortality after chronic total occlusion percutaneo us coronary intervention. Circ Cardiovasc Interv 2021; 14: e010923.
Xiong SQ, Chen Q, Chen X, et al. Adjustment of the GRACE score by the triglyceride glucose index improves the prediction of clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Cardiovasc Diabetol 2022; 21: 145.
Zhao Q, Zhang TY, Cheng YJ, et al. Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China. Cardiovasc Diabetol 2020; 19: 108.
Li Z, He YY, Wang S, et al. Association between triglyceride glucose index and carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China. Cardiovasc Diabe tol 2022; 21: 38.
Zhao YC, Lu XY, Wan F, et al. Disruption of circadian rhythms by shift work exacerbates reperfusion injury in myocardial infarction. J Am Coll Cardiol 2022; 79: 2097−2115.
Gao JW, Hao QY, Lu LY, et al. Associations of long-term physical activity trajectories with coronary artery calcium progression and cardiovascular disease events: results from the CARDIA study. Br J Sports Med 2022; 56: 854−861.
Li SD, Gao XJ, Yang JG, et al. Number of standard modifiable risk factors and mortality in patients with first-presentation ST-segment elevation myocardial infarction: insights from China Acute Myocardial Infarction registry. BMC Med 2022; 20: 217.
Wang YN, Gao XQ, Zhao ZJ, et al. Predictive value of type D personality for cardiovascular events in young patients with acute myocardial infarction: a prospective, observational study. Eur J Prev Cardiol 2022; 29: e100−e101.
Wang X, Zhao GQ, Zhou MG, et al. Trends in bleeding events among patients with acute coronary syndrome in China, 2015 to 2019: insights from the CCC-ACS project. Front Cardiovasc Med 2021; 8: 769165.
Chen L, Tan YL, Yu CQ, et al. Educational disparities in ischaemic heart disease among 0.5 million Chinese adults: a cohort study. J Epidemiol Community Health 2021; 75: 1033−1043.
853
Views
118
Downloads
1
Crossref
3
Web of Science
4
Scopus
0
CSCD
Altmetrics
京公网安备11010802044758号